Does sotagliflozin improve glycemic control in nonobese diabetes-prone mice with type 1 diabetes?
Sotagliflozin significantly improved glycemic control, without increasing the rate of hypoglycemia measurements, in diabetic mice maintained on a low insulin dose. This sotagliflozin-mediated improvement in glycemic control was comparable to that achieved by raising the insulin dose alone, but was not accompanied by the increased rate of hypoglycemia measurements observed with the higher insulin dose.
We first showed the expression of CD52 in human cumulus cells. CD52 has some functional roles around fertilization in females as well as in males.